Recent Price Movement and Market Context
On 2 March 2026, Jubilant Pharmova Ltd opened with a gap down of -5.34%, hitting an intraday low of Rs.820.05, which represents the lowest price level the stock has traded at in the past year. This decline extended a three-day losing streak, during which the stock has fallen by approximately -5.3%. The day’s performance saw the stock underperform its Pharmaceuticals & Biotechnology sector by -1.61%, while the broader Sensex index, despite a volatile session, managed to recover some losses and was trading at 80,095.24 points, down -1.47% for the day.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. In contrast, the Sensex, although trading below its 50-day moving average, maintains a positive technical structure with its 50-day average above the 200-day average.
Long-Term Performance and Relative Comparison
Over the past year, Jubilant Pharmova Ltd has recorded a negative return of -6.79%, significantly lagging behind the Sensex’s positive 9.42% gain and the BSE500’s 14.29% return. This underperformance highlights the stock’s challenges in keeping pace with broader market growth and sectoral trends.
The stock’s 52-week high was Rs.1,250, indicating a substantial decline of approximately 34.4% from its peak to the current low. This wide price range underscores the volatility and downward pressure experienced by the company’s shares over the last twelve months.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Performance Highlights
Jubilant Pharmova Ltd’s recent quarterly results have contributed to the subdued market sentiment. The company reported a Profit After Tax (PAT) of Rs.79.62 crores for the quarter ended December 2025, reflecting a decline of -31.1% compared to the previous corresponding period. Operating profit to interest coverage ratio also reached a low of 5.16 times, indicating tighter margins and increased financial leverage concerns.
Profit Before Tax (PBT) excluding other income stood at Rs.112.60 crores, down by -19.69% year-on-year. These figures highlight a contraction in profitability that has weighed on investor confidence and contributed to the stock’s downward pressure.
Growth Trends and Valuation Metrics
Over the last five years, the company’s operating profit has declined at an annualised rate of -8.16%, signalling challenges in sustaining long-term growth momentum. Despite this, the company’s Return on Capital Employed (ROCE) remains at a moderate 9.9%, which is relatively attractive within its sector.
Jubilant Pharmova Ltd’s valuation metrics suggest the stock is trading at a discount relative to its peers. The Enterprise Value to Capital Employed ratio stands at 1.8, indicating a potentially favourable valuation compared to historical averages within the Pharmaceuticals & Biotechnology sector. However, the company’s Price/Earnings to Growth (PEG) ratio is elevated at 5.6, reflecting the market’s cautious stance on its growth prospects.
Institutional Holdings and Market Perception
Institutional investors hold a significant stake in Jubilant Pharmova Ltd, accounting for 27.18% of the shareholding. This level of institutional ownership suggests that professional investors maintain a vested interest in the company’s fundamentals and outlook, despite the recent price weakness.
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector has experienced mixed performance in recent months, with some companies benefiting from innovation and demand growth, while others face pricing pressures and regulatory scrutiny. Jubilant Pharmova Ltd’s relative underperformance within this context has been notable, as it has lagged both sectoral and broader market indices.
Holding Jubilant Pharmova Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Rating Update
Jubilant Pharmova Ltd currently holds a Mojo Score of 28.0, categorised as a Strong Sell. This rating was upgraded from a Sell on 6 January 2026, reflecting a deterioration in the company’s financial and market metrics. The Market Capitalisation Grade is rated at 3, indicating a mid-tier market cap status within its sector.
Summary of Key Metrics
The stock’s recent price action, combined with its financial results and valuation, paints a picture of a company facing headwinds in growth and profitability. The 52-week low of Rs.820.05 is a tangible reflection of these challenges, with the stock trading well below all major moving averages and underperforming both sector and market benchmarks over the past year.
While the company’s ROCE and valuation ratios suggest some underlying value, the elevated PEG ratio and declining operating profit trend highlight ongoing concerns that have influenced market sentiment.
Investors and market participants will continue to monitor Jubilant Pharmova Ltd’s financial disclosures and sector developments to assess any shifts in its performance trajectory.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
